PARP inhibitors

PARP inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of pharmacological inhibitors targeting the PARP enzyme family. These enzymes play a critical role in DNA repair mechanisms, specifically in the repair of single-strand breaks via the base excision repair pathway. PARP inhibitors have gained significant attention in the field of oncology due to their therapeutic potential in treating various cancers, particularly those with deficiencies in homologous recombination repair, such as BRCA1 or BRCA2 mutations.

The PARP Inhibitors Market is expected to grow at a strong CAGR of 12.9% during the forecast period owing to increasing cancer cases. The rising incidence of cancer globally, coupled with advancements in diagnostic techniques that identify genetic mutations susceptible to PARP inhibitors, has driven the demand for these therapies. The increasing number of cancer cases and survivors emphasizes the need for effective, targeted treatments to improve patient outcomes, thereby fueling the growth of the PARP inhibitor market. According to the International Agency for Research on Cancer (IARC), there were approximately 20 million new cancer cases diagnosed globally in 2022. This number is projected to rise to 29.9 million by 2040 due to factors such as population growth, aging, and lifestyle changes.

• By drug type, the market is segmented into olaparib, niraparib, rucaparib, and others. The Olaparib segment held dominant share of the market in 2023. The olaparib segment in the PARP inhibitors market is witnessing significant growth due to its effectiveness in treating various types of cancers, particularly ovarian and breast cancers with BRCA mutations. Olaparib, marketed under the brand name Lynparza, is one of the most prominent PARP inhibitors and has gained widespread acceptance due to its ability to target and exploit DNA repair deficiencies in cancer cells, leading to cell death while sparing normal cells. The drug's success has been bolstered by extensive clinical trials demonstrating its efficacy and safety, leading to regulatory approvals in multiple regions. Additionally, olaparib's role in combination therapies and its expanding indications for use in prostate and pancreatic cancers further enhance its market presence. As a result, the olaparib segment is a key driver in the overall growth of the PARP inhibitors market, reflecting a strong trend toward targeted cancer therapies.
• Based on Application, the market is segmented into ovarian cancer, breast cancer, and others. The ovarian cancer segment held dominant share of the market in 2023. The ovarian cancer segment in the PARP inhibitors market has seen significant advancements, driven by the effectiveness of these inhibitors in treating BRCA-mutated ovarian cancer. According to the National Cancer Institute (NCI), ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States, with an estimated 21,410 new cases and 13,770 deaths expected in 2021. PARP inhibitors, such as olaparib, niraparib, and rucaparib, have revolutionized the treatment landscape for ovarian cancer by targeting DNA repair mechanisms, thus improving progression-free survival rates. The increasing incidence of ovarian cancer, coupled with the rising adoption of targeted therapies, continues to propel the growth of the ovarian cancer segment within the PARP inhibitors market.
• For a better understanding of the market adoption of the PARP Inhibitors industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share of the market in 2023. The North American PARP inhibitors market is a significant segment within the global oncology treatment landscape, driven by a high prevalence of cancers such as ovarian, breast, and prostate cancers. The U.S. leads the market due to its advanced healthcare infrastructure, significant research and development (R&D) investments, and favorable regulatory environment. In 2024, the PARP inhibitors market in North America is projected to continue its robust growth, driven by both established treatments and emerging therapies. For instance, in 2023, US FDA approved the combination of enzalutamide (Xtandi) and talazoparib (Talzenna) as an initial therapy for metastatic castration-resistant prostate cancer.
• Some of the major players operating in the market include AstraZeneca; Pfizer Inc.; Clovis Oncology, Inc.; Johnson & Johnson; Bristol Myers Squibb; AbbVie Inc.; Artios Pharma; Merck kGaA; Allarity Therapeutics, Inc.; and GlaxoSmithKline.